ERBB2 and neoplasm: Serum IL-18 levels remained as an important prognostic factor for both RFS and OS even after adjustment for other prognostic clinical variables, such as hormone receptor status, HER2 overexpression, tumor size, and nodal status (Supplementary Table 1).